Total Funding
70
13
Total FundingSeries B raised
Growth Score 70 in past quarter
-8 pts
Heat Score 13 in past quarter
-32 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
11710
ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines.
- Nick Pullen: Chief Scientific Officer
- Jonathan Freeman: Chief Business OfficerPast Role: Anthos Therapeutics, Founder and COO
About the Company
ARTBIO is a clinical-stage radiopharmaceutical biotechnology business that is working to create a new class of alpha radioligand medicines. ARTBIO is changing cancer care by creating a new class of alpha radioligand therapeutics (ART) and the ecosystem that supports.